EMA Withdrawn: Raplixa (human fibrinogen;human thrombin) — Mallinckrodt Pharmaceuticals Ireland Limited

View source ↗

Summary

Raplixa, a human fibrinogen and human thrombin product, has been withdrawn from the market by Mallinckrodt Pharmaceuticals Ireland Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemostasis Disorders
• Surgical Bleeding

Drugs mentioned

• Raplixa (TachoSil? Wait Raplixa is fibrin sealant containing human thrombin and fibrinogen known as Raplixa (topical tranexamic?))

Snippet

Status: Withdrawn. Therapeutic area: Hemostasis, Surgical. MAH: Mallinckrodt Pharmaceuticals Ireland Limited. Decision date: 19/03/2018